Tempest Therapeutics, Inc.

NasdaqCM:TPST Stock Report

Market Cap: US$27.6m

Tempest Therapeutics Management

Management criteria checks 2/4

Tempest Therapeutics' CEO is Steve Brady, appointed in Jun 2021, has a tenure of 3.42 years. total yearly compensation is $7.01M, comprised of 8.1% salary and 91.9% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $48.23K. The average tenure of the management team and the board of directors is 3.3 years and 3.4 years respectively.

Key information

Steve Brady

Chief executive officer

US$7.0m

Total compensation

CEO salary percentage8.1%
CEO tenure3.4yrs
CEO ownership0.2%
Management average tenure3.3yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

Tempest Therapeutics GAAP EPS of -$0.79

Aug 15

Tempest Therapeutics CEO Stephen Brady - Small Molecule Cancer Treatment

Jan 04

CEO Compensation Analysis

How has Steve Brady's remuneration changed compared to Tempest Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$32m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$7mUS$567k

-US$29m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$2mUS$530k

-US$36m

Sep 30 2022n/an/a

-US$34m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$715kUS$475k

-US$28m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$22m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$896kUS$461k

-US$19m

Compensation vs Market: Steve's total compensation ($USD7.01M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


CEO

Steve Brady (54 yo)

3.4yrs

Tenure

US$7,007,407

Compensation

Mr. Stephen R. Brady, also known as Steve, LL M., J.D. served as an Independent Director at Atreca, Inc. since July 2021. He has been Chief Executive Officer & Director at Tempest Therapeutics Inc. since J...


Leadership Team

NamePositionTenureCompensationOwnership
Stephen Brady
CEO, President & Director3.4yrsUS$7.01m0.17%
$ 48.2k
Nicholas Maestas
VP of Strategy & Finance and Secretary3.3yrsUS$1.32m0.033%
$ 9.0k
Samuel Whiting
Executive VP & Chief Medical Officer4yrsUS$3.38m0.036%
$ 10.0k
Justin Trojanowski
Corporate Controller2.2yrsno data0.083%
$ 23.1k
Lindsay Young
Head of Human Resourcesless than a yearno datano data

3.3yrs

Average Tenure

48.5yo

Average Age

Experienced Management: TPST's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stephen Brady
CEO, President & Director3.4yrsUS$7.01m0.17%
$ 48.2k
Christine Pellizzari
Independent Director3.3yrsUS$67.34k0%
$ 0
Michael Raab
Independent Chairman5.5yrsUS$107.84k0%
$ 0
Geoffrey Nichol
Independent Director3.4yrsUS$65.12k0%
$ 0
Andrew Pardoll
Member of Advisory Boardno datano datano data
Raymond DuBois
Member of Advisory Boardno datano datano data
Petpiboon Prasit
Member of Advisory Boardno datano datano data
Benjamin Cravatt
Member of Advisory Board5.5yrsno datano data
Ronit Simantov
Independent Director3.3yrsUS$57.62k0%
$ 0
Jason J. Luke
Member of Advisory Boardno datano datano data
Toni Choueiri
Member of Advisory Boardno datano datano data
Russell Vance
Member of Advisory Board3.2yrsno datano data

3.4yrs

Average Tenure

59yo

Average Age

Experienced Board: TPST's board of directors are considered experienced (3.4 years average tenure).